Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases

被引：1
作者：
Schulze-Koops, Hendrik [1 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Div Rheumatol & Clin Immunol, Dept Internal Med 4, Pettenkoferstr 8a, D-80336 Munich, Germany
来源：
RHEUMATOLOGY | 2017年 / 56卷
关键词：
BUDGET IMPACT ANALYSIS; PSORIATIC-ARTHRITIS; INFLIXIMAB; MANAGEMENT; BIOLOGICS; CT-P13; UPDATE;
D O I：
10.1093/rheumatology/kex275
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 3
页数：3
相关论文
共 15 条
  • [1] [Anonymous], 2014, GUID SIM BIOL MED PR
  • [2] Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
    Brodszky, Valentin
    Baji, Petra
    Balogh, Orsolya
    Pentek, Marta
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 : S65 - S71
  • [3] The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics
    Coates, Laura C.
    Tillett, William
    Chandler, David
    Helliwell, Philip S.
    Korendowych, Eleanor
    Kyle, Stuart
    McInnes, Iain B.
    Oliver, Susan
    Ormerod, Anthony
    Smith, Catherine
    Symmons, Deborah
    Waldron, Nicola
    McHugh, Neil J.
    [J]. RHEUMATOLOGY, 2013, 52 (10) : 1754 - 1757
  • [4] The road from development to approval: evaluating the body of evidence to confirm biosimilarity
    Declerck, Paul
    Rezk, Mourad Farouk
    [J]. RHEUMATOLOGY, 2017, 56 : 4 - 13
  • [5] The role of biosimilars in the treatment of rheumatic diseases
    Doerner, Thomas
    Strand, Vibeke
    Castaneda-Hernandez, Gilberto
    Ferraccioli, Gianfranco
    Isaacs, John D.
    Kvien, Tore K.
    Martin-Mola, Emilio
    Mittendorf, Thomas
    Smolen, Josef S.
    Burmester, Gerd R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (03) : 322 - 328
  • [6] Gartlehner G, 2006, J RHEUMATOL, V33, P2398
  • [7] Update on biologic therapies in ankylosing spondylitis: a literature review
    Goh, Leslie
    Samanta, Ash
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2012, 15 (05) : 445 - 454
  • [8] Biosimilars for the management of rheumatoid arthritis: economic considerations
    Gulacsi, Laszlo
    Brodszky, Valentin
    Baji, Petra
    Kim, HoUng
    Kim, Su Yeon
    Cho, Yu Young
    Pentek, Marta
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 : S43 - S52
  • [9] IMS Institute for HealthCare Informatics, 2016, DEL POT BIOS MED ROL
  • [10] Kim J, 2014, ARTHRITIS RHEUMATOL, V66, pS512
12